Sign in
DT

Dyne Therapeutics, Inc. (DYN)·Q4 2024 Earnings Summary

Executive Summary

  • Clinical and regulatory momentum strengthened: FDA granted Fast Track designation to DYNE-101 for DM1; Dyne set registrational expansion cohorts and timelines targeting U.S. Accelerated Approval submissions in H1 2026 (DYNE-101) and early 2026 (DYNE-251) .
  • Q4 2024 financials: net loss $89.5M and EPS $(0.88); cash and marketable securities were $0.642B at 12/31/24; additional $140.6M raised via ATM in Q1 2025; runway maintained into H2 2026 .
  • Operating spend rose year over year with R&D at $81.8M (vs $58.8M) and G&A at $15.3M (vs $8.8M), reflecting program advancement .
  • Catalysts: full enrollment for DELIVER (DYNE-251) cohort in Q1 2025 with late-2025 data; ACHIEVE (DYNE-101) cohort full enrollment by mid-2025 with H1 2026 data supporting accelerated approval; investor event and ongoing FDA dialogue underpin narrative that can move shares on regulatory clarity and clinical readouts .

What Went Well and What Went Wrong

What Went Well

  • FDA Fast Track designation for DYNE-101; management emphasized “substantial functional benefit… reversal of disease progression” and rapid move to registrational expansion aimed at accelerated approval in H1 2026 .
  • Robust DM1 data: 6.8 mg/kg Q8W dose showed CASI splicing correction at 3 months associated with functional improvements; vHOT improved 38% (−2.9 sec) at 6 months; MDHI total improved 44% at 6 months, with CNS subscale signals (sleep, cognitive impairment, fatigue, etc.) .
  • Safety remained favorable: DYNE-101 with 855 doses and 72 patient-years, no related serious TEAEs; DYNE-251 with 837 doses and 65 patient-years, favorable safety profile with no new related SAEs since prior update .

Management quotes:

  • “We are moving rapidly to initiate a Registrational Expansion Cohort to support a potential submission for U.S. Accelerated Approval.” — John Cox, CEO .
  • “DM1… is heterogenous… We believe our FORCE platform can deliver medicines broadly and deeply… enabling DYNE-101 to uniquely address the broad manifestations of the disease.” — Doug Kerr, CMO .

What Went Wrong

  • Higher operating expenses YoY: R&D rose to $81.8M (Q4 2024) vs $58.8M (Q4 2023); G&A rose to $15.3M vs $8.8M, increasing quarterly net loss to $89.5M (though EPS improved from $(1.09) due to share count) .
  • Splicing data variability: a 6-month CASI data point at high dose was deemed a technical outlier (missing baseline, biopsy variability), requiring clarification; reliance on CASI as a surrogate endpoint may face regulatory scrutiny and demands robust confirmatory functional data .
  • Consensus estimates unavailable at time of analysis due to S&P Global rate-limit errors, limiting formal beat/miss assessment for EPS/Revenue; will need update for trading comparison once accessible [GetEstimates error].

Financial Results

MetricQ4 2023Q2 2024Q3 2024Q4 2024
Research and development ($USD Millions)$58.8 $62.3 $92.8 $81.8
General and administrative ($USD Millions)$8.8 $9.7 $12.9 $15.3
Total operating expenses ($USD Millions)$67.7 $71.96 $105.66 $97.11
Other (expense) income, net ($USD Millions)$1.05 $6.86 $8.53 $7.57
Net loss ($USD Millions)$66.64 $65.10 $97.13 $89.54
Net loss per share ($USD)$(1.09) $(0.70) $(0.96) $(0.88)
Cash, cash equivalents and marketable securities ($USD Millions)$123.10 $778.84 $723.67 $642.27; +$140.6 ATM in Q1’25
Weighted avg shares outstanding (Millions)61.39 92.51 100.88 101.98

Notes:

  • Dyne did not report product revenues; condensed statements focus on operating expenses, other income, and net loss .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
DYNE-101 (DM1) U.S. Accelerated Approval submissionH1 2026Pursuing accelerated approval; registration path update by year-end 2024 Submission targeted H1 2026; Fast Track granted Clarified timeline; regulatory status upgraded (Fast Track)
ACHIEVE Registrational Expansion Cohort (DYNE-101)Enrollment & endpointsPlan to initiate; ~32-patient cohort Global, placebo-controlled; up to 48 patients; full enrollment mid-2025; primary endpoint CASI-22 at 3 months Cohort size increased; timeline specified
DYNE-251 (DMD) Registrational Expansion CohortEnrollment & data timing20 mg/kg Q4W; ~32 participants; complete Q1 2025; late-2025 data Maintained: complete Q1 2025; late-2025 data; pursue AA based on dystrophin surrogate Maintained; FDA feedback affirmed dystrophin surrogate
DYNE-251 U.S. Accelerated Approval submissionEarly 2026Pursuing AA; cohort enrolling Submission early 2026 Clarified timeline
Cash runwayThrough H2 2026At least into H2 2026 Into H2 2026; plus ~$140.6M ATM in Q1 2025 Maintained; liquidity strengthened

Earnings Call Themes & Trends

TopicQ2 2024 (previous mentions)Q3 2024 (previous mentions)Q4 2024 (current period)Trend
Regulatory path (Accelerated Approval)Pursuing AA; splicing as surrogate; update by YE 2024 IND cleared for DYNE-101; expedited pathways; registrational cohort plan Fast Track for DYNE-101; detailed registrational plans; AA timing set (H1 2026/Early 2026) Strengthening regulatory clarity
Surrogate endpoint (CASI)CASI utility discussed; design evolving Plan to report 6.8 mg/kg data to guide dose CASI at 3 months tied to functional benefit; MMRM approach; outlier clarified Increasing confidence; technical nuance noted
Safety profileFavorable across both programs (cutoffs Q2) Favorable; ongoing enrollment Favorable; DYNE-101: 855 doses/72 patient-years; DYNE-251: 837 doses/65 patient-years Stable positive
CNS effects (DM1)Platform CNS delivery in preclinical highlighted Anticipated broader benefit MDHI total −44% and CNS subscales improvement at 6.8 mg/kg; management positioning as differentiator Emerging differentiator
DMD dystrophin/functionDose-dependent dystrophin; unprecedented levels vs historical benchmark; functional trends (NSAA, SV95C) Enrolling registrational 20 mg/kg cohort Maintained; AA path based on dystrophin; late-2025 data goal On track

Management Commentary

  • “Our most recent clinical data for DYNE-101… showed substantial functional benefit… We believe… benefits… result from addressing the underlying biology… through meaningful splicing correction.” — John Cox, CEO .
  • “We are excited to have selected the dose for our Registrational Expansion Cohort… Our FORCE platform can deliver medicines broadly and deeply into relevant tissues…” — Doug Kerr, CMO .
  • “We anticipate readouts from our registrational expansion cohorts in 2025 and 2026… well capitalized to advance the pipeline.” — John Cox, investor event .

Q&A Highlights

  • CASI as surrogate and predictive power: Management affirmed crossing a CASI threshold (>20%) at 5.4/6.8 mg/kg predicts functional benefit; cited forthcoming manuscript and FDA dialogue aligning on requirements .
  • Splicing outlier at 6 months: Clarified as technical (missing baseline, biopsy variability), not biology; robustness supported by deepening DMPK knockdown and functional improvements .
  • Statistical methodology: MMRM to adjust for baseline imbalances; standard approach expected to be acceptable to FDA; plans to power for CASI and vHOT while tracking strength/function/PRO directionality .
  • Data rollout and timelines: DELIVER 6-month dystrophin endpoint enabling late-2025 readout; ACHIEVE 3-month CASI and 6-month function aimed for early 2026 data; blinded safety tables maintained .
  • CNS differentiation: MDHI CNS subscales improvement viewed as robust and differentiating; platform CNS delivery emphasized .

Estimates Context

  • Wall Street consensus (S&P Global) EPS and revenue estimates for Q2–Q4 2024 and FY 2024 were unavailable at time of request due to SPGI rate-limit errors; therefore, formal beat/miss vs consensus cannot be assessed in this recap. We will update estimate comparisons when S&P Global data access is restored [GetEstimates error].

Key Takeaways for Investors

  • Fast Track for DYNE-101 and clearly articulated accelerated approval timelines are material de-risking events; watch for ACHIEVE enrollment completion by mid-2025 and H1 2026 submission target .
  • DM1 efficacy signals span myotonia (−38% vHOT) and broader function (QMT +10.1% from baseline) with encouraging CNS PROs (MDHI −44%), supporting a potentially differentiated label narrative if sustained in registrational cohort — a key medium-term thesis driver .
  • DYNE-251 remains on a near-term path: full enrollment Q1 2025, late-2025 data, early-2026 submission; AA based on dystrophin surrogate aligns with recent FDA feedback — key trading catalyst into late-2025 .
  • Liquidity is strong: $0.642B cash at 12/31/24 plus $140.6M ATM in Q1 2025; runway into H2 2026 supports execution through pivotal milestones without near-term financing overhang .
  • Technical risks exist around reliance on surrogate endpoints (CASI, dystrophin) and biopsy-based measures; management’s plan (powering endpoints, MMRM adjustments, functional co-measures) mitigates but does not eliminate regulatory uncertainty — monitor FDA interactions closely .
  • Operating expenses are elevated given registrational execution; sequencing of data readouts (late-2025 DMD; early-2026 DM1) defines the stock’s catalyst path and risk/reward profile through 2026 .
  • Near-term: positioning trades around enrollment completions and any incremental FDA/regulatory disclosures; medium-term: thesis hinges on confirmatory functional benefits aligning with surrogate endpoints to secure AA and support potential 2027 launches .